Mechanisms mediating the ability of caffeine to influence MDMA (‘Ecstasy’)‐induced hyperthermia in rats
Authors:
Open Access
- 24 May 2010
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 160 (4) , 860-877
Abstract
Background and purpose: Caffeine exacerbates the hyperthermia associated with an acute exposure to 3,4 methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) in rats. The present study investigated the mechanisms mediating this interaction.Experimental approach: Adult male Sprague‐Dawley rats were treated with caffeine (10 mg·kg−1; i.p.) and MDMA (15 mg·kg−1; i.p.) alone and in combination. Core body temperatures were monitored before and after drug administration.Key results: Central catecholamine depletion blocked MDMA‐induced hyperthermia and its exacerbation by caffeine. Caffeine provoked a hyperthermic response when the catecholamine releaserd‐amphetamine (1 mg·kg−1) was combined with the 5‐HT releaserd‐fenfluramine (5 mg·kg−1) or the non‐selective dopamine receptor agonist apomorphine (1 mg·kg−1) was combined with the 5‐HT2receptor agonist DOI (2 mg·kg−1) but not following either agents alone. Pretreatment with the dopamine D1receptor antagonist Schering (SCH) 23390 (1 mg·kg−1), the 5‐HT2receptor antagonist ketanserin (5 mg·kg−1) or α1‐adreno‐ receptor antagonist prazosin (0.2 mg·kg−1) blocked MDMA‐induced hyperthermia and its exacerbation by caffeine. Co‐administration of a combination of MDMA with the PDE‐4 inhibitor rolipram (0.025 mg·kg−1) and the adenosine A1/2receptor antagonist 9‐chloro‐2‐(2‐furanyl)‐[1,2,4]triazolo[1,5‐C]quinazolin‐5‐amine 15943 (10 mg·kg−1) or the A2Areceptor antagonist SCH 58261 (2 mg·kg−1) but not the A1receptor antagonist DPCPX (10 mg·kg−1) exacerbated MDMA‐induced hyperthermia.Conclusions and implications: A mechanism comprising 5‐HT and catecholamines is proposed to mediate MDMA‐induced hyperthermia. A combination of adenosine A2Areceptor antagonism and PDE inhibition can account for the exacerbation of MDMA‐induced hyperthermia by caffeine.Keywords
This publication has 76 references indexed in Scilit:
- Guide to Receptors and Channels (GRAC), 4th editionBritish Journal of Pharmacology, 2009
- Phosphodiesterase 5 inhibitors prevent 3,4‐methylenedioxymethamphetamine‐induced 5‐HT deficits in the ratJournal of Neurochemistry, 2009
- Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neuronsPharmacology Biochemistry and Behavior, 2008
- Serotonin 5-HT2BReceptors Are Required for 3,4-Methylenedioxymethamphetamine-Induced Hyperlocomotion and 5-HT ReleaseIn VivoandIn VitroJournal of Neuroscience, 2008
- Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brainFrontiers in Bioscience-Landmark, 2008
- Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies2008
- Effects of 3,4-methylenedioxymethamphetamine and related amphetamines on autonomic and behavioral thermoregulationPharmacology Biochemistry and Behavior, 2005
- Attenuation of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced rhabdomyolysis with α 1 - plus β 3 -adrenoreceptor antagonistsBritish Journal of Pharmacology, 2004
- Results of Contracture Tests with Halothane, Caffeine, and Ryanodine Depend on Different Malignant Hyperthermia-associated Ryanodine Receptor Gene MutationsAnesthesiology, 2002
- Clinically Significant Pharmacokinetic Interactions Between Dietary Caffeine and MedicationsClinical Pharmacokinetics, 2000